Table 3.

Infection and treatment among COVID-19-positive blood cultures (n = 58)

Characteristic	Contaminant (n = 33)	True BSI (n = 25)	p value
Pathogen
Candida	0	3 (12)	0.08
Coagulase-negative Staph	27 (82)	9 (36)	< 0.01
Enterobacterales	0	2 (8.0)	0.18
Enterococcus	0	4 (16)	0.03
Staphylococcus aureus	0	5 (20)	0.01
Pseudomonadales	0	0	–
Antibiotic used, any	28 (85)	20 (80)	0.73
Antifungals	0	6 (24)	< 0.01
Anti-MRSA agents	18 (55)	18 (72)	0.18
Vancomycin	18 (55)	17 (68)	0.30
Linezolid, daptomycin, ceftaroline	3 (9)	4 (16)	0.45
Beta-lactams	27 (82)	20 (80)	1.0
Penicillins	1 (3)	2 (8)	0.57
First-generation cephalosporins	1 (3)	4 (16)	0.15
Third-generation cephalosporins	21 (64)	12 (48)	0.23
Fourth-generation cephalosporins	14 (42)	16 (64)	0.10
Carbapenems	3 (9.1)	6 (24)	0.15
Fluoroquinolones	1 (3)	1 (4)	1.0
Macrolides	7 (21)	12 (48)	0.03
Tetracyclines	17 (52)	9 (36)	0.24
Antibiotic treatment
Antibiotics per patient; median (IQR)	2.0 (2.0)	4.0 (3.0)	0.07
Abx DOT per patient, days; median	8.0 (12.5)	10 (13.5)	0.69
Abx DOT per antibiotic, days; median	3.0 (3.4)	2.7 (3.3)	0.45
Abx Consumption, DOT per 1000 patient-days; median	800 (1339)	652 (593)	0.34

MRSA methicillin-resistant Staphylococcus aureus, Abx antibiotics, DOT days of therapy